Lung Cancer Resources

Cancer Treatment Research and Sources of Information & Support

Kenneth S. Pope, Ph.D., ABPP

The resources on this page are intended to help people with lung cancer and their loved ones to find information, support, and other resources. These resources are meant to complement and not replace any advice or information from a health care professional. This site is designed to be fully accessible for people with disabilities; please follow this link to change text size, color, or contrast; please follow this link for other accessibility functions for those with visual, mobility, and other disabilities.

There are 4 sections of resources:

1) Books

2) Recent research articles on lung cancer treatments

3) Recent article on psychological aspects of lung cancer

4) Links to web sites providing information and support for people with lung cancer, their loved ones, and clinicians

PLEASE NOTE: This web site includes 6 other pages of related sets of resources:

BOOKS:

Lung Cancer: The Facts, 3rd Edition by Stephen Falk & Chris Williams. Oxford University Press, 2010.
Johns Hopkins Patients' Guide to Lung Cancer by Justin F. Klamerus, Julie R. Brahmer, & David S Ettinger. Jones & Bartlett Publishers, 2010.
The Cleveland Clinic Guide to Lung Cancer by Peter Mazzone. Kaplan Publishing, 2009.
100 Questions and Answers about Lung Cancer by Karen Parles & Joan Schiller. Jones & Bartlett, 2011.
Be A Survivor: Lung Cancer Treatment Guide by Vladimir Lange. Lange Publications, 2009.
QuickFACTS: Lung Cancer by American Cancer Society. American Cancer Sociation, 2010.

RECENT (I.E., PUBLISED IN 2011) RESEARCH ARTICLES ON TREATMENT APPROACHES FOR LUNG CANCER:

Ahmad, E., Sandhu, A. P., Fuster, M. M., Messer, K., Pu, M., Nobiensky, P., et al. (2011). Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients. American journal of clinical oncology, 34(3), 254-258.
Bae, M. K., Byun, C. S., Lee, C. Y., Lee, J. G., Park, I. K., Kim, D. J., et al. (2011). The role of surgical treatment in second primary lung cancer. The Annals of thoracic surgery, 92(1), 256-262.
Baker, M., Nielsen, M., Hansen, O., Jahn, J. W., Korreman, S., & Brink, C. (2011). Isotoxic Dose Escalation in the Treatment of Lung Cancer by Means of Heterogeneous Dose Distributions in the Presence of Respiratory Motion. International journal of radiation oncology, biology, physics.
Baldwin, D. R., White, B., Schmidt-Hansen, M., Champion, A. R., & Melder, A. M. (2011). Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ, 342, d2110.
Banna, G. L., Di Maio, M., Follador, A., Collova, E., Menis, J., Novello, S., et al. (2011). Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung cancer, 73(1), 78-88.
Bar Ad, V., Ohri, N., & Werner-Wasik, M. (2011). Esophagitis, Treatment-Related Toxicity In Non-Small Cell Lung Cancer. Reviews on recent clinical trials.
Bolukbas, S., Ghezel-Ahmadi, D., Kudelin, N., Biancosino, C., Eberlein, M., & Schirren, J. (2011). Sleeve resections for the treatment of non-small cell lung cancer. Minerva chirurgica, 66(4), 329-339.
Bonner, J. A., Willey, C. D., Yang, E. S., Dobelbower, M. C., Sanford, L. L., Bright, S. J., et al. (2011). Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
Brocken, P., Kiers, B. A., Looijen-Salamon, M. G., Dekhuijzen, P. N., Smits-van der Graaf, C., Peters-Bax, L., et al. (2011). Timeliness of lung cancer diagnosis and treatment in a rapid outpatient diagnostic program with combined (18)FDG-PET and contrast enhanced CT scanning. Lung cancer.
Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J. R., Georgoulias, V., et al. (2011). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.
Burger, J. A., Stewart, D. J., Wald, O., & Peled, A. (2011). Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. [Research Support, Non-U.S. Gov't Review]. Expert review of anticancer therapy, 11(4), 621-630.
Carbone, D. P., & Felip, E. (2011). Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clinical lung cancer, 12(5), 261-271.
Cataldo, V. D., Gibbons, D. L., Perez-Soler, R., & Quintas-Cardama, A. (2011). Treatment of non-small-cell lung cancer with erlotinib or gefitinib. [Review]. The New England journal of medicine, 364(10), 947-955.
Chang, C. C., Chi, K. H., Kao, S. J., Hsu, P. S., Tsang, Y. W., Chang, H. J., et al. (2011). Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung cancer, 73(2), 189-194.
Chang, J. W., Thongprasert, S., Wright, E., Tsang, K., Kim, H. T., Ahn, M. J., et al. (2011). An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial]. Asia-Pacific journal of clinical oncology, 7 Suppl 2, 13-21.
Chen, L. K., Huang, H., Liao, H., Liu, G. Z., Zeng, Y. D., Dinglin, X. X., et al. (2011). Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study. Medical oncology.
Chen, X., Li, W., Hu, X., Geng, Y., Wang, R., Yin, Y., et al. (2011). Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
Cheng, J., Xu, J., Duanmu, J., Zhou, H., Booth, C. J., & Hu, Z. (2011). Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy. Current cancer drug targets.
Cheon, Y. H., Kim, M. J., Kang, M. G., Kim, H. J., Lee, S. S., Kim, C. Y., et al. (2011). Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer. Yonsei medical journal, 52(4), 695-698.
Chien, C. W., Yao, J. H., Chang, S. Y., Lee, P. C., & Lee, T. C. (2011). Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicology and applied pharmacology.
Chiou, J. F., Wu, A. T., Wang, W. T., Kuo, T. H., Gelovani, J. G., Lin, I. H., et al. (2011). A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging. Evidence-based complementary and alternative medicine : eCAM, 2011, 914561.
Coate, L. E., Massey, C., Hope, A., Sacher, A., Barrett, K., Pierre, A., et al. (2011). Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(3), 537-544.
D'Incecco, A., & Cappuzzo, F. (2011). Gefitinib for non-small-cell lung cancer treatment. Expert opinion on drug safety.
Dahabreh, I. J., Linardou, H., Kosmidis, P., Bafaloukos, D., & Murray, S. (2011). EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. [Meta-Analysis Research Support, Non-U.S. Gov't Review]. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 22(3), 545-552.
de Boer, R. H., Arrieta, O., Yang, C. H., Gottfried, M., Chan, V., Raats, J., et al. (2011). Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(8), 1067-1074.
De Sanctis, A., Taillade, L., Vignot, S., Novello, S., Conforti, R., Spano, J. P., et al. (2011). Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. [Review]. Cancer, 117(14), 3069-3080.
Diaconescu, R., Lafond, C., & Whittom, R. (2011). Treatment delays in non-small cell lung cancer and their prognostic implications. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(7), 1254-1259.
Dienstmann, R., & Felip, E. (2011). Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert opinion on biological therapy, 11(9), 1223-1231.
Eccles, B. K., Geldart, T. R., Laurence, V. M., Bradley, K. L., & Lwin, M. T. (2011). Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. Therapeutic advances in medical oncology, 3(4), 163-170.
Edelman, M. J., Otterson, G., Leach, J., Malpass, T., Salgia, R., Jones, D., et al. (2011). Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. [Clinical Trial, Phase II]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(4), 786-789.
Ellis, P. M., Blais, N., Soulieres, D., Ionescu, D. N., Kashyap, M., Liu, G., et al. (2011). A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(8), 1379-1391.
Faller, B. A., & Pandit, T. N. (2011). Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clinical Medicine Insights. Oncology, 5, 131-144.
Fanucchi, O., Ambrogi, M. C., Dini, P., Lucchi, M., Melfi, F., Davini, F., et al. (2011). Surgical treatment of non-small cell lung cancer in octogenarians. Interactive cardiovascular and thoracic surgery, 12(5), 749-753.
Forde, P., Murphy, C., O'Sullivan, C., & Carney, D. (2011). Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer. [Case Reports]. Irish journal of medical science, 180(1), 283-284.
Foster, N. R., Qi, Y., Shi, Q., Krook, J. E., Kugler, J. W., Jett, J. R., et al. (2011). Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. [Meta-Analysis Research Support, N.I.H., Extramural]. Cancer, 117(6), 1262-1271.
Fujiwara, Y., Hotta, K., Di Maio, M., Kiura, K., Takigawa, N., Tabata, M., et al. (2011). Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. [Clinical Trial, Phase III]. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 22(2), 376-382.
Gajra, A., & Lichtman, S. M. (2011). Treatment of advanced lung cancer in the elderly. [Review]. Hospital practice, 39(2), 107-115.
Genestreti, G., Giovannini, N., Frizziero, M., Maglie, M., Sanna, S., Cingarlini, S., et al. (2011). Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study. Journal of chemotherapy, 23(4), 232-237.
Glattki, G. P., Manika, K., Sichletidis, L., Alexe, G., Brenke, R., & Spyratos, D. (2011). Pulmonary Rehabilitation in Non-small Cell Lung Cancer Patients After Completion of Treatment. American journal of clinical oncology.
Govindan, R. (2011). Hope without hype: EML4-ALK inhibition for treatment of lung cancer. [Letter]. The lancet oncology.
Gridelli, C. (2011). First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy? [Editorial]. Current opinion in oncology, 23(2), 131-132.
Gridelli, C., Ardizzoni, A., Barni, S., Crino, L., Caprioli, A., Piazza, E., et al. (2011). Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung cancer.
Gridelli, C., Bennouna, J., de Castro, J., Dingemans, A. M., Griesinger, F., Grossi, F., et al. (2011). Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical lung cancer.
Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., & Mok, T. (2011). Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. [Research Support, Non-U.S. Gov't Review]. Lung cancer, 72(1), 3-8.
Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., & Mok, T. (2011). Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. [Research Support, Non-U.S. Gov't]. Lung cancer, 71(3), 249-257.
Gridelli, C., Rossi, A., Venturino, P., & de Marinis, F. (2011). Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. [Clinical Trial, Phase II Randomized Controlled Trial]. Clinical lung cancer, 12(1), 70-73.
Gridelli, C., Stahel, R., Besse, B., Ciardiello, F., Felip, E., Gasparini, S., et al. (2011). Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung cancer.
Hainsworth, J. D., Fang, L., Huang, J. E., Karlin, D., Russell, K., Faoro, L., et al. (2011). BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. [Clinical Trial, Phase II Multicenter Study]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(1), 109-114.
Hanai, J. I., Doro, N., Sasaki, A. T., Kobayashi, S., Cantley, L. C., Seth, P., et al. (2011). Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways. Journal of cellular physiology.
Hayashi, H., Kurata, T., & Nakagawa, K. (2011). Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. Clinical Medicine Insights. Oncology, 5, 177-184.
Healey, T. T., & Dupuy, D. E. (2011). Radiofrequency ablation: a safe and effective treatment in nonoperative patients with early-stage lung cancer. [Review]. Cancer journal, 17(1), 33-37.
Hermes, A., Waschki, B., Gatzemeier, U., & Reck, M. (2011). Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis. Lung cancer, 71(3), 363-366.
Hirsh, V. (2011). Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Current oncology, 18(3), 126-138.
Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W. E., et al. (2011). Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(19), 2667-2674.
Hodkinson, P. S., & Sethi, T. (2011). Advances in the prevention and treatment of lung cancer. The journal of the Royal College of Physicians of Edinburgh, 41(2), 142-149.
Holt, G. E., Podack, E. R., & Raez, L. E. (2011). Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy, 8(1), 43-54.
Holy, R., Piroth, M., Pinkawa, M., & Eble, M. J. (2011). Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 187(4), 245-251.
Horiike, A., Kudo, K., Miyauchi, E., Ohyanagi, F., Kasahara, K., Horai, T., et al. (2011). Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British journal of cancer.
Hsu, L. H., Chen, Y. P., Chang, H. P., Chen, Y. R., Hong, J. H., Chao, A., et al. (2011). Successful salvage treatment of recurrent endometrial cancer with multiple lung and abdominal metastases. [Case Reports]. European journal of gynaecological oncology, 32(2), 218-220.
Huang, C. H., Williamson, S. K., Van Veldhuizen, P. J., Hsueh, C. T., Allen, A., Tawfik, O., et al. (2011). Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(2), 372-377.
Ibeas, P., Cantos, B., Gasent, J. M., Rodriguez, B., & Provencio, M. (2011). PET-CT in the staging and treatment of non-small-cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 13(6), 368-377.
Iranzo, V., Sirera, R., Carrato, A., Cabrera, A., Jantus, E., Guijarro, R., et al. (2011). Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 13(6), 411-418.
Isla, D., Gonzalez-Rojas, N., Nieves, D., Brosa, M., & Finnern, H. W. (2011). Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. [Research Support, Non-U.S. Gov't]. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 13(7), 460-471.
Jensen, A. D., Munter, M. W., Bischoff, H. G., Haselmann, R., Haberkorn, U., Huber, P. E., et al. (2011). Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. [Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. Cancer, 117(13), 2986-2994.
Jimenez, M. F., Varela, G., Van Baardwijk, A., & De Ruysscher, D. (2011). Radiotherapy issues in non-small cell lung cancer: radiotherapy versus surgery in the treatment of early stage. [Comparative Study]. Minerva chirurgica, 66(3), 245-250.
Jotte, R., Conkling, P., Reynolds, C., Galsky, M. D., Klein, L., Fitzgibbons, J. F., et al. (2011). Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. [Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(3), 287-293.
Jung, E. J., Lee, J. H., Jeon, K., Koh, W. J., Suh, G. Y., Chung, M. P., et al. (2011). Treatment outcomes for patients with synchronous multiple primary non-small cell lung cancer. [Research Support, Non-U.S. Gov't]. Lung cancer, 73(2), 237-242.
Kalemkerian, G. P. (2011). Advances in the treatment of small-cell lung cancer. Seminars in respiratory and critical care medicine, 32(1), 94-101.
Kates, M., Swanson, S., & Wisnivesky, J. P. (2011). Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. [Comparative Study]. Chest, 139(3), 491-496.
Kim, B. M., Maeng, K., Lee, K. H., & Hong, S. H. (2011). Combined treatment with the Cox-2 inhibitor niflumic acid and PPARgamma ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. [Research Support, Non-U.S. Gov't]. Cancer letters, 300(2), 134-144.
Kim, Y. M., & Pyo, H. (2011). Cooperative Enhancement of Radiosensitivity After Combined Treatment of 17-(Allylamino)-17-Demethoxygeldanamycin and Celecoxib in Human Lung and Colon Cancer Cell Lines. DNA and cell biology.
Kodama, H., Yamakado, K., Takaki, H., Kashima, M., Uraki, J., Nakatsuka, A., et al. (2011). Lung Radiofrequency Ablation for the Treatment of Unresectable Recurrent Non-Small-Cell Lung Cancer After Surgical Intervention. Cardiovascular and interventional radiology.
Kolodziejczyk, M., Kepka, L., Dziuk, M., Zawadzka, A., Szalus, N., Gizewska, A., et al. (2011). Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. [Evaluation Studies]. International journal of radiation oncology, biology, physics, 80(4), 1008-1014.
Kurtze, I., Sonnemann, J., & Beck, J. F. (2011). KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. [Research Support, Non-U.S. Gov't]. Oncology reports, 25(4), 1021-1029.
Langer, C. J. (2011). Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. P & T : a peer-reviewed journal for formulary management, 36(5), 263-279.
Lestuzzi, C., Bearz, A., Lafaras, C., Gralec, R., Cervesato, E., Tomkowski, W., et al. (2011). Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. [Multicenter Study]. Lung cancer, 72(3), 340-347.
Lin, H. P., Kuo, L. K., & Chuu, C. P. (2011). Combined Treatment of Curcumin and Small Molecule Inhibitors Suppresses Proliferation of A549 and H1299 Human Non-Small-Cell Lung Cancer Cells. Phytotherapy research : PTR.
Lind, J. S., Lagerwaard, F. J., Smit, E. F., Postmus, P. E., Slotman, B. J., & Senan, S. (2011). Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer. Cancer, 117(3), 597-605.
Liu, S., Wang, D., Chen, B., Wang, Y., Zhao, W., & Wu, J. (2011). The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung cancer, 73(2), 203-210.
Manegold, C., van Zandwijk, N., Szczesna, A., Zatloukal, P., Au, J. S., Blasinska-Morawiec, M., et al. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.
Melloni, G., Bandiera, A., Gregorc, V., Carretta, A., Ciriaco, P., Vigano, M., et al. (2011). Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience. The Journal of cardiovascular surgery, 52(4), 613-619.
Mohammed, N., Kestin, L. L., Grills, I. S., Battu, M., Fitch, D. L., Wong, C. Y., et al. (2011). Rapid disease progression with delay in treatment of non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 79(2), 466-472.
Moran, C. (2011). Importance of molecular features of non-small cell lung cancer for choice of treatment. [Research Support, Non-U.S. Gov't Review]. The American journal of pathology, 178(5), 1940-1948.
Motta, M., Del Vecchio, A., Attuati, L., Picozzi, P., Perna, L., Franzin, A., et al. (2011). Gamma Knife Radiosurgery for Treatment of Cerebral Metastases from Non-Small-Cell Lung Cancer. International journal of radiation oncology, biology, physics.
Murphy, M., & Stordal, B. (2011). Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. [Research Support, Non-U.S. Gov't Review]. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 14(3), 177-190.
Nair, B. S., Bhanderi, V., & Jafri, S. H. (2011). Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clinical Medicine Insights. Oncology, 5, 223-234.
Nguewa, P. A., Calvo, A., Pullamsetti, S. S., Banat, G. A., Grimminger, F., & Savai, R. (2011). Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. [Research Support, Non-U.S. Gov't Review]. Expert opinion on investigational drugs, 20(1), 61-74.
Nishiyama, O., Taniguchi, H., Kondoh, Y., Takada, K., Baba, K., Saito, H., et al. (2011). Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. Anti-cancer drugs, 22(8), 811-816.
O'Brien, M. E., Konopa, K., Lorigan, P., Bosquee, L., Marshall, E., Bustin, F., et al. (2011). Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. European journal of cancer.
Palma, D., Lagerwaard, F., Rodrigues, G., Haasbeek, C., & Senan, S. (2011). Curative Treatment of Stage I Non-small-cell Lung Cancer in Patients with Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review. International journal of radiation oncology, biology, physics.
Palma, D., & Senan, S. (2011). Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. [Research Support, Non-U.S. Gov't Review]. Current opinion in oncology, 23(2), 133-139.
Pennell, N. A. (2011). Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non-Small-cell Lung Cancer. Clinical lung cancer.
Platania, M., Agustoni, F., Formisano, B., Vitali, M., Ducceschi, M., Pietrantonio, F., et al. (2011). Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted oncology, 6(3), 181-186.
Pua, B. B., Thornton, R. H., & Solomon, S. B. (2011). Radiofrequency ablation: treatment of primary lung cancer. Seminars in roentgenology, 46(3), 224-229.
Qi, W. X., Shen, Z., & Yao, Y. (2011). Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology.
Rahn, D. A., 3rd, Ray, D. K., Schlesinger, D. J., Steiner, L., Sheehan, J. P., O'Quigley, J. M., et al. (2011). Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer, 117(2), 414-420.
Rinaldi, F., George, E., & Clark, P. (2011). NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer. [News]. The lancet oncology, 12(8), 728-730.
Rivera, C., Dahan, M., Bernard, A., Falcoz, P. E., & Thomas, P. (2011). Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 39(6), 981-986.
Romero-Ventosa, E. Y., Mucientes-Molina, A., Pedrido-Reino, E., Lago-Rivero, N., Constenla-Carames, L., & Arias-Santos, I. (2011). Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
Rossi, A., Torri, V., & Gridelli, C. (2011). Switch maintenance versus second-line treatment in non-small cell lung cancer. [Letter]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(7), 1298.
Sacco, P. C., Maione, P., Rossi, A., Bareschino, M. A., Schettino, C., Guida, C., et al. (2011). Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Targeted oncology, 6(3), 171-180.
Salgia, R., Hensing, T., Campbell, N., Salama, A. K., Maitland, M., Hoffman, P., et al. (2011). Personalized treatment of lung cancer. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Seminars in oncology, 38(2), 274-283.
Satoh, H., Inoue, A., Kobayashi, K., Maemondo, M., Oizumi, S., Isobe, H., et al. (2011). Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. [Research Support, Non-U.S. Gov't]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(8), 1413-1417.
Scagliotti, G., Brodowicz, T., Shepherd, F. A., Zielinski, C., Vansteenkiste, J., Manegold, C., et al. (2011). Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. [Comparative Study Research Support, Non-U.S. Gov't]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(1), 64-70.
Seo, J. U., Kim, M. H., Kim, H. M., & Jeong, H. J. (2011). Anticancer potential of magnolol for lung cancer treatment. [Research Support, Non-U.S. Gov't]. Archives of pharmacal research, 34(4), 625-633.
Shapiro, A. C., & Swenson, K. K. (2011). Nutritional challenges during treatment for lung cancer. Oncology nursing forum, 38(5), 515-518.
Skrzypski, M., Dziadziuszko, R., & Jassem, J. (2011). MicroRNA in lung cancer diagnostics and treatment. Mutation research.
Solano-Reina, S., De Granda-Orive, J. I., & Jimenez-Ruiz, C. A. (2011). Smoking Cessation: An Essential Component in the Treatment of Lung Cancer Patients. [Letter]. Archivos de bronconeumologia, 47(9), 477.
Song, X., Varker, H., Eichelbaum, M., Stopfer, P., Shahidi, M., Wilson, K., et al. (2011). Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes. Lung cancer, 74(1), 103-111.
Song, Z. B., Yu, Y. F., Chen, Z. W., & Lu, S. (2011). Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chinese medical journal, 124(15), 2279-2283.
Spigel, D. R., Hainsworth, J. D., Shipley, D. L., Ervin, T. J., Kohler, P. C., Lubiner, E. T., et al. (2011). A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
Standfield, L., Weston, A. R., Barraclough, H., van Kooten, M., & Pavlakis, N. (2011). Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology.
Stinchcombe, T. E., Peterman, A. H., Lee, C. B., Moore, D. T., Beaumont, J. L., Bradford, D. S., et al. (2011). A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age >/=70 years) with stage IIIB/IV non-small cell lung cancer. [Research Support, Non-U.S. Gov't]. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(9), 1569-1577.
Sudhindra, A., Ochoa, R., & Santos, E. S. (2011). Biomarkers, Prediction, and Prognosis in Non-Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical lung cancer.
Syrigos, K. N., Saif, M. W., Karapanagiotou, E. M., Oikonomopoulos, G., & De Marinis, F. (2011). The need for third-line treatment in non-small cell lung cancer: an overview of new options. [Review]. Anticancer research, 31(2), 649-659.
Tanaka, S., Sakamori, Y., Niimi, M., Hazama, M., Kim, Y. H., & Yanagihara, K. (2011). Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST). [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]. Trials, 12, 120.
Tartarone, A., Lerose, R., Gallucci, G., Ardito, R., & Aieta, M. (2011). Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical oncology.
Tassinari, D., Sartori, S., Papi, M., Drudi, F., Castellani, C., Carloni, F., et al. (2011). Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. Oncology, 80(5-6), 350-358.
Thornton, M., Parry, M., Gill, P., Mead, D., & Macbeth, F. (2011). Hard choices: a qualitative study of influences on the treatment decisions made by advanced lung cancer patients. International journal of palliative nursing, 17(2), 68-74.
Timmerman, R. D., & Fernando, H. C. (2011). From the guest editors: treatment of early-stage lung cancer. [Editorial]. Cancer journal, 17(1), 1-2.
Tournoux-Facon, C., Senellart, H., Lemarie, E., Tourani, J. M., Favrel, S., Pouget, J. C., et al. (2011). Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(7), 1247-1253.
Umemura, S., Yamane, H., Suwaki, T., Katoh, T., Yano, T., Shiote, Y., et al. (2011). Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. Journal of cancer research and clinical oncology, 137(10), 1469-1475.
Utzschneider, S., Wicherek, E., Weber, P., Schmidt, G., Jansson, V., & Durr, H. R. (2011). Surgical treatment of bone metastases in patients with lung cancer. International orthopaedics, 35(5), 731-736.
van der Meij, B. S., Phernambucq, E. C., Fieten, G. M., Smit, E. F., Paul, M. A., van Leeuwen, P. A., et al. (2011). Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(9), 1563-1568.
Vandy, B. (2011). Lung cancer and surgical treatment. Kentucky nurse, 59(2), 4-5.
Wanders, R., Steevens, J., Botterweck, A., Dingemans, A. M., Reymen, B., Baardwijk, A. V., et al. (2011). Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: A prospective population-based study. European journal of cancer.
Wong, H. L., & de Boer, R. H. (2011). Vandetanib for the treatment of non-small-cell lung cancer. Expert opinion on pharmacotherapy, 12(14), 2271-2278.
Wozniak, A. (2011). Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical reviews in oncology/hematology.
Wu, S., & Keresztes, R. S. (2011). Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. [Research Support, Non-U.S. Gov't]. Cancer investigation, 29(7), 460-471.
Xenidis, N., Vardakis, N., Varthalitis, I., Giassas, S., Kontopodis, E., Ziras, N., et al. (2011). Alpha multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]. Cancer chemotherapy and pharmacology, 68(1), 63-68.
Xu, X. H., Su, J., Fu, X. Y., Xue, F., Huang, Q., Li, D. J., et al. (2011). Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. [Clinical Trial
Research Support, Non-U.S. Gov't]. Cancer chemotherapy and pharmacology, 67(2), 475-479.
Xu, Z. Y., Jin, C. J., Zhou, C. C., Wang, Z. Q., Zhou, W. D., Deng, H. B., et al. (2011). Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Journal of cancer research and clinical oncology, 137(7), 1117-1122.
Yamashita, S., Chujo, M., Kawano, Y., Miyawaki, M., Tokuishi, K., Anami, K., et al. (2011). Clinical impact of segmentectomy compared with lobectomy under complete video-assisted thoracic surgery in the treatment of stage I non-small cell lung cancer. [Comparative Study]. The Journal of surgical research, 166(1), 46-51.
Yoo, D. C., Dupuy, D. E., Hillman, S. L., Fernando, H. C., Rilling, W. S., Shepard, J. A., et al. (2011). Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome? [Research Support, N.I.H., Extramural]. AJR. American journal of roentgenology, 197(2), 334-340.
Yoo, D. G., Kim, Y. H., Kim, D. K., Kim, H. R., & Park, S. I. (2011). Clinical feasibility and surgical benefits of video-assisted mediastinoscopic lymphadenectomy in the treatment of resectable lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
Yu, D. H., Li, J. H., Wang, Y. C., Xu, J. G., Pan, P. T., & Wang, L. (2011). Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. [Research Support, Non-U.S. Gov't]. Clinica chimica acta; international journal of clinical chemistry, 412(11-12), 930-935.
Zhang, A. Y., Zyzanski, S. J., & Siminoff, L. A. (2011). Ethnic differences in the caregiver's attitudes and preferences about the treatment and care of advanced lung cancer patients. Psycho-oncology.
Zhang, H., Yun, S., Batuwangala, T. D., Steward, M., Holmes, S. D., Pan, L., et al. (2011). A Dual-Targeting Antibody against EGFR-VEGF for Lung and Head and Neck Cancer Treatment. International journal of cancer. Journal international du cancer.
Zhang, S., Zheng, Y., Yu, P., Yu, F., Zhang, Q., Lv, Y., et al. (2011). The combined treatment of CT-guided percutaneous (125)I seed implantation and chemotherapy for non-small-cell lung cancer. Journal of cancer research and clinical oncology.
Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. [Research Support, Non-U.S. Gov't]. The lancet oncology, 12(8), 735-742.
Zhou, Q., Zhang, X. C., Chen, Z. H., Yin, X. L., Yang, J. J., Xu, C. R., et al. (2011). Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. [Research Support, Non-U.S. Gov't]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(24), 3316-3321.

RECENT ARTICLES (i.e., PUBLISHED IN 2009, 2010, OR 2011) ON PSYCHOLOGICAL ASPECTS OF LUNG CANCER (e.g., PSYCHOSOCIAL FACTORS & SURVIVAL; SUPPORTIVE CARE NEEDS OF PEOPLE WITH LUNG CANCER; COMPLICATED GRIEF SYMPTOMS IN CAREGIVERS OF PEOPLE WITH LUNG CANCER):

PLEASE NOTE: The articles below focus specifically on lung cancer. Another page of this site addresses psychological aspects of all types of cancer: Psychological Interventions for People with Cancer: Therapy & Self-Help.

Akechi, T., Okamura, H., Okuyama, T., Furukawa, T. A., Nishiwaki, Y., & Uchitomi, Y. (2009). Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. Psycho-Oncology, 18(1), 23-29.
Akin, S., Can, G., Aydiner, A., Ozdilli, K., & Durna, Z. (2010). Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. European Journal of Oncology Nursing, 14(5), 400-409.
Berendes, D., Keefe, F. J., Somers, T. J., Kothadia, S. M., Porter, L. S., & Cheavens, J. S. (2010). Hope in the context of lung cancer: Relationships of hope to symptoms and psychological distress. Journal of Pain and Symptom Management, 40(2), 174-182.
Chan, C. W. H., Richardson, A., & Richardson, J. (2011). Managing symptoms in patients with advanced lung cancer during radiotherapy: Results of a psychoeducational randomized controlled trial. Journal of Pain and Symptom Management, 41(2), 347-357.
Dorman, S., Hayes, J., & Pease, N. (2009). What do patients with brain metastases from non-small cell lung cancer want from their treatment? Palliative Medicine, 23(7), 594-600.
Floyd, A., Dedert, E., Ghate, S., Salmon, P., Weissbecker, I., Studts, J. L., et al. (2011). Depression may mediate the relationship between sense of coherence and quality of life in lung cancer patients. Journal of Health Psychology, 16(2), 249-257.
Kramer, B. J., Kavanaugh, M., Trentham-Dietz, A., Walsh, M., & Yonker, J. A. (2010). Predictors of family conflict at the end of life: The experience of spouses and adult children of persons with lung cancer. The Gerontologist, 50(2), 215-225.
Kramer, B. J., Kavanaugh, M., Trentham-Dietz, A., Walsh, M., & Yonker, J. A. (2010). Complicated grief symptoms in caregivers of persons with lung cancer: The role of family conflict, intrapsychic strains, and hospice utilization. Omega: Journal of Death and Dying, 62(3), 201-220.
Lee, L. J.-H., Chung, C.-W., Chang, Y.-Y., Lee, Y.-C., Yang, C.-H., Liou, S.-H., et al. (2011). Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation, 20(3), 415-423.
Lehto, R., & Therrien, B. (2010). Death concerns among individuals newly diagnosed with lung cancer. Death Studies, 34(10), 931-946.
Lindau, S. T., Surawska, H., Paice, J., & Baron, S. R. (2011). Communication about sexuality and intimacy in couples affected by lung cancer and their clinical-care providers. Psycho-Oncology, 20(2), 179-185.
Milette, K., El-Baalbaki, G., & Thombs, B. D. (2010). Intimacy processes and psychological distress among couples coping with head and neck or lung cancer. Psycho-Oncology, 19(11), 1235-1236.
Mulcare, H., Schofield, P., Kashima, Y., Milgrom, J., Wirth, A., Bishop, M., et al. (2011). Adjustment to cancer and the information needs of people with lung cancer. Psycho-Oncology, 20(5), 488-496.
Porter, L. S., Keefe, F. J., Garst, J., Baucom, D. H., McBride, C. M., McKee, D. C., et al. (2011). Caregiver-assisted coping skills training for lung cancer: Results of a randomized clinical trial. Journal of Pain and Symptom Management, 41(1), 1-13.
Sanders, S. L., Bantum, E. O., Owen, J. E., Thornton, A. A., & Stanton, A. L. (2010). Supportive care needs in patients with lung cancer. Psycho-Oncology, 19(5), 480-489.